TY - JOUR
T1 - Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity
T2 - a systematic review and metaanalysis of individual patient data
AU - Romero, Roberto
AU - Nicolaides, Kypros
AU - Conde-Agudelo, Agustin
AU - Tabor, Ann
AU - O'Brien, John M
AU - Cetingoz, Elcin
AU - Da Fonseca, Eduardo
AU - Creasy, George W
AU - Klein, Katharina
AU - Rode, Line
AU - Soma-Pillay, Priya
AU - Fusey, Shalini
AU - Cam, Cetin
AU - Alfirevic, Zarko
AU - Hassan, Sonia S
N1 - Copyright © 2012. Published by Mosby, Inc.
PY - 2012/2
Y1 - 2012/2
N2 - Objective: To determine whether the use of vaginal progesterone in asymptomatic women with a sonographic short cervix (≤25 mm) in the midtrimester reduces the risk of preterm birth and improves neonatal morbidity and mortality. Study Design: Individual patient data metaanalysis of randomized controlled trials. Results: Five trials of high quality were included with a total of 775 women and 827 infants. Treatment with vaginal progesterone was associated with a significant reduction in the rate of preterm birth <33 weeks (relative risk [RR], 0.58; 95% confidence interval [CI], 0.420.80), <35 weeks (RR, 0.69; 95% CI, 0.550.88), and <28 weeks (RR, 0.50; 95% CI, 0.300.81); respiratory distress syndrome (RR, 0.48; 95% CI, 0.300.76); composite neonatal morbidity and mortality (RR, 0.57; 95% CI, 0.400.81); birthweight <1500 g (RR, 0.55; 95% CI, 0.380.80); admission to neonatal intensive care unit (RR, 0.75; 95% CI, 0.590.94); and requirement for mechanical ventilation (RR, 0.66; 95% CI, 0.440.98). There were no significant differences between the vaginal progesterone and placebo groups in the rate of adverse maternal events or congenital anomalies. Conclusion: Vaginal progesterone administration to asymptomatic women with a sonographic short cervix reduces the risk of preterm birth and neonatal morbidity and mortality.
AB - Objective: To determine whether the use of vaginal progesterone in asymptomatic women with a sonographic short cervix (≤25 mm) in the midtrimester reduces the risk of preterm birth and improves neonatal morbidity and mortality. Study Design: Individual patient data metaanalysis of randomized controlled trials. Results: Five trials of high quality were included with a total of 775 women and 827 infants. Treatment with vaginal progesterone was associated with a significant reduction in the rate of preterm birth <33 weeks (relative risk [RR], 0.58; 95% confidence interval [CI], 0.420.80), <35 weeks (RR, 0.69; 95% CI, 0.550.88), and <28 weeks (RR, 0.50; 95% CI, 0.300.81); respiratory distress syndrome (RR, 0.48; 95% CI, 0.300.76); composite neonatal morbidity and mortality (RR, 0.57; 95% CI, 0.400.81); birthweight <1500 g (RR, 0.55; 95% CI, 0.380.80); admission to neonatal intensive care unit (RR, 0.75; 95% CI, 0.590.94); and requirement for mechanical ventilation (RR, 0.66; 95% CI, 0.440.98). There were no significant differences between the vaginal progesterone and placebo groups in the rate of adverse maternal events or congenital anomalies. Conclusion: Vaginal progesterone administration to asymptomatic women with a sonographic short cervix reduces the risk of preterm birth and neonatal morbidity and mortality.
KW - Administration, Intravaginal
KW - Female
KW - Humans
KW - Pregnancy
KW - Pregnancy Trimester, Second
KW - Premature Birth
KW - Progesterone
KW - Progestins
KW - Risk
KW - Treatment Outcome
U2 - 10.1016/j.ajog.2011.12.003
DO - 10.1016/j.ajog.2011.12.003
M3 - Journal article
C2 - 22284156
SN - 0002-9378
VL - 206
SP - 124.e1-19
JO - American Journal of Obstetrics & Gynecology
JF - American Journal of Obstetrics & Gynecology
IS - 2
ER -